



PATENT ATTORNEY DOCKET NO. 04843/117002

Certificate of Mailing: Date of Deposit: June 16, 2005
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Santa Zingariello Printed name of person mailing correspondence Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Perry F. Renshaw et al.

Art Unit:

1623

Serial No.:

10/740,075

Examiner:

Matthew L. Fedowitz

Filed:

December 17, 2003

Customer No.:

21559

Title:

COMPOUNDS FOR THE NORMALIZATION OF THE

SLEEP/WAKE CYCLE

06/21/2005 WASFAW1 00000010 10740075

01 FC:1806

180.00 OP

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the reference listed on the enclosed Form PTO-1449, a copy of which is enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: 16 Opene 2005

grep L. Elbing, Ph.D

Reg. No. 35,238

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

DATE CARS



Sheet _1_ of _1_

BSTITUTE FORM PTO-	1449
(MODIFIED)	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Attorney Docket No.

04843/117002

Serial No.

10/740,075

INFORMATION DISCLOSURE

Applicant

Perry F. Renshaw et al.

STATEMENT BY APPLICANT (Use several sheets if necessary)

Filing Date

December 17, 2003

Group

1623

(37 C.F.R. § 1.98(b))

IDS Filed

June 16, 2005

Examiner's Initials	U.S. PATENT DOCUMENTS							
Examiner's Initials Document Number Publication Date Patent Office Class Subclass Translation (Yes/No) OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases,"				Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)	
Examiner's Initials Document Number Publication Date Patent Office Class Subclass Translation (Yes/No) OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases,"								
Examiner's Initials Document Number Publication Date Patent Office Class Subclass Translation (Yes/No) OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases,"	_							
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases,"		FORE	EIGN PATENT (OR PUBLISHED FOREIGN PATENT A	PPLICATIO	N N		
Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases,"				Country or Patent Office	Class	Subclass		
Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases,"								
Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases,"							!	
Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases," Arzneimittelforschung. Drug Res. 33:1073-1080 (1983).		OTHER DOCL	JMENTS (INCL	UDING AUTHOR, TITLE, DATE, PLAC	E OF PUB	LICATION)		
	Fernandez, "Efficacy and Safety of Oral CDP-Choline: Drug Surveillance Study in 2817 Cases," Arzneimittelforschung. Drug Res. 33:1073-1080 (1983).							
				•				
			_					
					. •	_		

FΧΔ	NΛ	IN	F	R

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.